We are committed to finding a cure for WM.

Medical/Research Updates

1 2 3 8

Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia

Source: https://www.cancertherapyadvisor.com/hematologic-cancers/waldenstrom-macroglobulinemia-zanubrutinib-new-trial-treatment/article/801383/

A head-to-head, open-label, multicenter, phase 3 clinical trial comparing the efficacy and safety of zanubrutinib (BGB-3111) with ibrutinib in patients with Waldenström macroglobulinemia (WM) is underway (ClinicalTrials.org Identifier: NCT03053440).1 The study also seeks to evaluate the… Continue reading

Article: Exploring Use of Ibrutinib/Rituximab Combination for Waldenström Macroglobulinemia

JULY 06, 2018
Kristi Rosa
 
 

A type of non-Hodgkin lymphoma, Waldenström macroglobulinemia is a rare, slow-growing lymphoproliferative disorder that is estimated to affect only 1,000 to 1,500 individuals each year in the… Continue reading

FDA Grants Priority Review to Waldenstrom’s Macroglobulinemia Combination Therapy

Source: https://www.raredr.com/news/waldenstroms-macroglobulinemia-combination-therapy-receives-new-drug-designation

Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc announced that the US Food and Drug Administration (FDA) has granted Priority Review for a supplemental New Drug Application (sNDA) for the company’s Waldenström’s macroglobulinemia combination therapy, ibrutinib (IMBRUVICA)… Continue reading

Video: IMBRUVICA (ibrutinib) in Combination With Rituximab for Waldenstrom’s Macroglobulinemia

The following link is to the Cancer Therapy Advisor website featuring the following video

IMBRUVICA (ibrutinib) in Combination With Rituximab for Waldenstrom’s Macroglobulinemia

Meletios Dimopoulos, MD, discusses his findings at the ASCO 2018 meeting in Chicago.

Full link:

https://www.cancertherapyadvisor.com/asco-2018/imbruvica-ibrutinib-combination-rituximab-waldenstrom-macroglobulinemia/article/770910/

1 2 3 8